OBJECTIVE	To identify a molecular signature that could be predictive of the clinical response to rituximab ( RTX ) and elucidate the transcriptomic changes after RTX therapy in patients with rheumatoid arthritis ( RA ) , with the use of whole-blood transcriptomic profiling .\